Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy, refractory to radioactive iodine when radioactive iodine was appropriate.
LAMPGEN ANALYSIS
Why it matters
Added a selective RET inhibitor option for thyroid cancers meeting fusion and prior radioiodine criteria.
What research teams should watch
Confirm the fusion and document whether radioactive iodine was appropriate and why the disease was refractory.
PRIMARY RECORDS